The prognostic performance of Diadem’s biomarker test in predicting progression to Alzheimer’s dementia was high, with “area under the curve” values (a measure of the accuracy of a quantitative diagnostic test) above 0.90 for both preclinical pre-symptomatic patients and for prodromal stage patients beginning to manifest early dementia symptoms.
The study results
The study results indicated promising positive and negative predictive values of about 90% when predicting the progression to AD dementia more than 6 years prior to symptom onset.
The Diadem biomarker test also achieved high diagnostic performance in the ability to differentiate cognitively normal individuals from patients with AD dementia.
This is good news for the millions of families worldwide who will confront AD in the coming years, since our simple, accessible blood-based assay will allow for therapeutic interventions early in the disease process, when slowing or stopping disease progression is far more feasible. It will also enable more effective clinical trials of investigative therapies for AD. We look forward to sharing the full results from the Clinical Validation study in the coming months.
Our simple, affordable and accessible blood-based technology will enable individuals to be widely screened in primary care settings, setting the stage for achieving tangible progress against this devastating disease that could benefit millions of people worldwide.